Fosun Pharma expands international reach with Sirusli license in Korea

Shanghai Fosun Pharmaceutical Group (SSE:600196) is strategically expanding its international presence through its holding subsidiary, Henlius, by granting Alvogen Korea exclusive rights to commercialize Sirusli (斯鲁利单抗) injection in South Korea. The license covers a range of significant cancer indications including extensive stage of small cell lung cancer (ES-SCLC), non-squamous non-small cell lung cancer (nsNSCLC), metastatic colorectal cancer (mCRC), gastric cancer (GC), and esophageal squamous cell carcinoma (ESCC).